Literature DB >> 21327616

Our impasse in developing a malaria vaccine.

Michael F Good1.   

Abstract

Malaria presents a challenge to world health that to date has been beyond the abilities of researchers to conquer. This critique presents some of the strategies employed by the parasite to overcome immunity and the immunological challenges that we face to develop vaccines. A conclusion is that a vaccine must identify novel antigens or epitopes that are not normally immunogenic and which are therefore not under immune pressure and most likely to be conserved between different strains. Such antigens are most likely to be targets of cellular immunity. The case for a whole parasite blood stage vaccine is presented based on these premises.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327616     DOI: 10.1007/s00018-011-0634-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  60 in total

1.  Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design.

Authors:  Junhui Duan; Jianbing Mu; Mahamadou Ali Thera; Deirdre Joy; Sergei L Kosakovsky Pond; David Diemert; Carole Long; Hong Zhou; Kazutoyo Miura; Amed Ouattara; Amagana Dolo; Ogobara Doumbo; Xin-Zhuan Su; Louis Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-30       Impact factor: 11.205

2.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.

Authors:  M F Good; D Pombo; I A Quakyi; E M Riley; R A Houghten; A Menon; D W Alling; J A Berzofsky; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

3.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

4.  Development of cellular immune responses to Plasmodium falciparum blood stage antigens from birth to 36 months of age in Cameroon.

Authors:  Jean-Yves Le Hesran; Nadine Fiévet; Jean Thioulouse; Philippe Personne; Bertrand Maubert; Samuel M'bidias; Daniel Etye'ale; Michel Cot; Philippe Deloron
Journal:  Acta Trop       Date:  2006-07-03       Impact factor: 3.112

5.  Inhibition of Plasmodium falciparum in vitro by human gamma delta T cells.

Authors:  M M Elloso; H C van der Heyde; J A vande Waa; D D Manning; W P Weidanz
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

6.  Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children.

Authors:  Marthe C D'Ombrain; Leanne J Robinson; Danielle I Stanisic; Jack Taraika; Nicholas Bernard; Pascal Michon; Ivo Mueller; Louis Schofield
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

7.  Antibody-independent immunity to reinfection malaria in B-cell-deficient mice.

Authors:  J L Grun; W P Weidanz
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

8.  Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line.

Authors:  D A Brake; C A Long; W P Weidanz
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

9.  Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

Authors:  Shannon L Takala; Drissa Coulibaly; Mahamadou A Thera; Adrian H Batchelor; Michael P Cummings; Ananias A Escalante; Amed Ouattara; Karim Traoré; Amadou Niangaly; Abdoulaye A Djimdé; Ogobara K Doumbo; Christopher V Plowe
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

10.  Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Authors:  Mark E Polhemus; Shon A Remich; Bernhards R Ogutu; John N Waitumbi; Lucas Otieno; Stella Apollo; James F Cummings; Kent E Kester; Christian F Ockenhouse; Ann Stewart; Opokua Ofori-Anyinam; Isabelle Ramboer; Conor P Cahill; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Amanda Leach; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more
  3 in total

1.  Mixed results for a malaria vaccine.

Authors:  Victor Nussenzweig; Michael F Good; Adrian V S Hill
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

Review 2.  Immunization in travel medicine.

Authors:  Suzanne Moore Shepherd; William Hudson Shoff
Journal:  Prim Care       Date:  2011-12       Impact factor: 2.907

3.  Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.

Authors:  Marcela Parra; Xia Liu; Steven C Derrick; Amy Yang; Alvaro Molina-Cruz; Carolina Barillas-Mury; Hong Zheng; Phuong Thao Pham; Martha Sedegah; Arnel Belmonte; Dianne D Litilit; Thomas A Waldmann; Sanjai Kumar; Sheldon L Morris; Liyanage P Perera
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.